Study outcomes among patients receiving GVAX/placebo vaccinations after HSCT
| Outcome . | GVAX . | Placebo . | P . |
|---|---|---|---|
| Grade II-IV acute GVHD at 1 y | 34% (4-31) | 12% (2.8-27) | .13 |
| Grade III-IV acute GVHD at 1 y | 16% (4.7-33) | 0% | .09 |
| Chronic GVHD at 3 y | 47% (27-64) | 59% (37-76) | .26 |
| Moderate to severe chronic GVHD at 3 y | 23% (10-40) | 33% (16-52) | .42 |
| 18-mo PFS* | 53% (34-69) | 55% (35-72) | .79 |
| 18-mo OS | 63% (43-77) | 59% (38-75) | .86 |
| 18-mo NRM | 17% (6-32) | 7.7% (12-22) | .18 |
| 18-mo relapse | 30% (15-47) | 37% (19-55) | .51 |
| Outcome . | GVAX . | Placebo . | P . |
|---|---|---|---|
| Grade II-IV acute GVHD at 1 y | 34% (4-31) | 12% (2.8-27) | .13 |
| Grade III-IV acute GVHD at 1 y | 16% (4.7-33) | 0% | .09 |
| Chronic GVHD at 3 y | 47% (27-64) | 59% (37-76) | .26 |
| Moderate to severe chronic GVHD at 3 y | 23% (10-40) | 33% (16-52) | .42 |
| 18-mo PFS* | 53% (34-69) | 55% (35-72) | .79 |
| 18-mo OS | 63% (43-77) | 59% (38-75) | .86 |
| 18-mo NRM | 17% (6-32) | 7.7% (12-22) | .18 |
| 18-mo relapse | 30% (15-47) | 37% (19-55) | .51 |
Values in parentheses given as 95% confidence intervals. ECOG, Eastern Cooperative Oncology Group.
Primary end point.